


Emergent BioSolutions Product Portfolio

As of May 2010



1. A critical human clinical study has begun and is expected to proceed in parallel with non-clinical studies under the FDA "Animal Rule."
 2. Licensed to Oxford-Emergent Tuberculosis Consortium Ltd. from Isis Innovation Ltd., the commercialization arm of Oxford University.

To view information about Emergent product development, please refer to the Company's Form 10-K.

ALL INVESTIGATIONAL PRODUCTS MUST SUCCESSFULLY COMPLETE THEIR RESPECTIVE DEVELOPMENT PROGRAMS AND BE APPROVED BY THE FDA (AND/OR FOREIGN EQUIVALENTS) BEFORE THEY MAY BE MARKETED.

BioThrax® and Typhella™ are trademarks of Emergent BioSolutions.